Sera Prognostics Investor Relations Material

Sera Prognostics, Inc. is a women's health diagnostic company that discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company offers Sera Maternal Test (SMT), a non-invasive prenatal test (NIPT) that measures cell-free DNA in maternal blood to detect fetal DNA circulating in the maternal circulation; and Sera F uture Study (SFS), an NIPT for detecting trisomy 18. Its products also comprise Sera MaternalTest Direct Prenatal Test I.